Abida W et al. Phase I study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer progressing on enzalutamide. Clin Cancer Res 2024;30(6):1111-20. Abstract
Aggarwal RR et al. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). ASCO 2024;Abstract 5012.
Attard G et al. Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial. ESMO 2023;Abstract 1806P.
Chi KN et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 2023;41(18):3339-51. Abstract
Churchill TW et al. Cardiac structural changes and declining cardiorespiratory fitness during androgen deprivation therapy for prostate cancer. J Am Soc Echocardiogr 2024:[Online ahead of print]. Abstract
De Bono JS et al. Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore. ASCO 2024;Abstract 5008.
Denmeade SR et al. Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial. ASCO 2024;Abstract LBA5014.
Fleshner NE et al. A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study. ASCO 2024;Abstract LBA5002.
Gao X et al. A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study. ASCO 2023;Abstract TPS5111.
Halabi S et al. A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance). ASCO 2024;Abstract 5007.
Halabi S et al. Assessing PSA. ESMO 2023;Abstract 1837P.
Halabi S et al. Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). ASCO 2023;Abstract 5070.
Higano CS et al. Clinical outcomes and treatment patterns in REASSURE: Planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. EClinicalMedicine 2023;60:101993. Abstract
Hussain M et al. BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mRCPR) bearing homologous recombination-repair mutations (HRRm). Genitourinary Cancers Symposium 2024;Abstract 19.
Hussain M et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. JAMA Oncol 2024;10(6):807-20. Abstract
McKay RR et al. CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). ESMO 2022;Abstract 1423TiP.
Mobadersany P et al. AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). ASCO 2023;Abstract 5027.
Morris MJ et al. A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC). ASCO 2024;Abstract 5010.
Petrylak DP et al. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. ASCO 2024;Abstract 5011.
Saylor PJ et al. Circulating and imaging biomarkers of radium-223 response in metastatic castration-resistant prostate cancer. JCO Precis Oncol 2024;e2300230. Abstract
Saylor PJ et al. The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancer. Radiother Oncol 2024;192:110091. Abstract
Shen J et al. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer 2024;130(1):73-81. Abstract
Smith MR et al. CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer. ASCO 2024;Abstract 5001.
Smith MR et al. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. J Manag Care Spec Pharm 2023;29(7):758-68. Abstract
Smith MR et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol 2022;23(3):362-73. Abstract
Turco F et al. Safety profile of darolutamide versus placebo: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2023;[Online ahead of print]. Abstract